The Warfarin-Aspirin Recurrent Stroke Study (WARSS): Initial Results
The Warfarin-Aspirin Recurrent Stroke Study (WARSS) enrolled 2206 patients from 47 US centers with acute ischemic stroke within 30 days of onset and randomized them to a double-blinded two-year treatment program of aspirin 325 mg per day or warfarin doses of 2 mg tablets sufficient to maintain a target INR of 1.4–2.8 determined monthly or more often. The INR studies were performed in one central laboratory. The Columbia University Data Management Center blinded the INR values to ensure patients and local invesigators could not determine which of the two active treatments was applicable to any patient. Endpoints of death recurrent stroke, together with complications, were adjudicated by committees whose members were also blinded as to therapy. The trial ended 31-Jul-2000 with final data planned for analysis beginning 30-Oct-2000. Initial results are expected to be completed for presentation at the 26th Conference. Data may also be available for outcomes from four parallel studies of the same patient cohort concerning antiphospholipid status (APASS), patent cardiac foramen ovale (PICSS), hemostatic coagulation factors (HAS), and genetics (GENESIS).